Macular Degeneration Therapeutics - Pipeline Assessment and Market Forecasts to 2018

Sept. 9, 2011 - PRLog -- GlobalData estimates that the global macular degeneration therapeutics market was valued at $2,800m in 2010, and is forecast to grow at a Compound Annual Growth Rate (CAGR) of 6.4% over the next eight
years, to reach $4,620m by 2018. This significant growth is primarily attributed to an increase in treatment rates which will result in an increase in the treated patient pool and a high annual cost of therapy of the approved market drugs for wet Age-related Macular Degeneration (AMD) which will drive the market valuations. The market has experienced significant growth due to the introduction of anti-VEGF (Vascular Endothelial Growth Factor) drugs for the treatment of wet AMD. Currently there are no approved therapies available for dry AMD. Antioxidants are used to slow down the progression of both dry and wet AMD.

The leading companies in the global macular degeneration therapeutics market are Genentech/Roche,
Osi Pharmaceuticals/Eyetech Inc. and QLT Ltd/Novartis. Together, these companies account for more
than 90% of the global wet AMD therapeutics market. Genentech/Roche, with its blockbuster drug Lucentis (ranibizumab), was the market leader in 2009. Lucentis was launched in US by Genentech/Roche and

in the rest of the world by Novartis. The companies such as Bayer/Regeneron Pharma, Alcon/Novartis,
Adeona Pharma, Ophthotech Corp, Pfizer Inc, Acucela Inc, Alimera Sciences, Neurotech Pharma and Allergan Inc have the most technologically advanced products in their pipeline portfolios and are expected to attract most of the investor’s attention. The global macular degeneration therapeutics market has seen some intense competition in recent times, which is expected to further intensify over the coming years.

For Sample Pages, please click or add the below link to your browser:
http://www.globaldata.com/reportstore/RequestSamplePages....

GlobalData’s analysis shows that the macular degeneration therapeutics pipeline is strong and contains
96 molecules in different phases of development. More than 70% of the pipeline drugs are first-in-class
and the rest are me-too’s and combination therapies. The first-in-class molecules have distinct advantages over the currently marketed products for wet AMD in terms of efficacy and better safety profiles, and have the potential to satisfy the unmet need in the market. However, the prevailing market
landscape remains dominated by a small number of market players which moderately fulfill the unmet
needs that exist in the market. Some products, currently under clinical investigation, are expected to receive approval from regulatory agencies’ in the next few years. However, the majority of these products differ from the existing class of products and will offer more improvements in terms of safety and efficacy. This would make the existing market leaders face significant challenges to their market shares. Essentially, the global macular degeneration therapeutics market is heading towards an increasingly competitive and dynamic landscape.

GlobalData, the industry analysis specialist, has released its new report, “Macular Degeneration Therapeutics - Pipeline Assessment and Market Forecasts to 2018”. The report is an essential source of information and analysis on the global macular degeneration therapeutics market. The report identifies the key trends shaping and driving the global macular degeneration therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global macular degeneration therapeutics
sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts

For further details, please click or add the below link to your browser:
http://www.globaldata.com/reportstore/Report.aspx?ID=Macu...

Visit our report store: http://www.globaldata.com/reportstore

For more details contact:
pressreleases@globaldata.com
           
North America:    +1 646 395 5477
Europe:        +44 207 753 4299
           +44 1204 543 533
Asia Pacific:       +91 40 6616 6782

# # #

GlobalData is a global market intelligence services company providing information research and analysis products and services.